A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin

Sponsor
GlaxoSmithKline (Industry)
Overall Status
Completed
CT.gov ID
NCT03093181
Collaborator
(none)
157
1
3
4.8
32.7

Study Details

Study Description

Brief Summary

This study is designed to evaluate the cosmetic benefit provided by twice daily application of a developmental moisturising cream with niacinamide for 8 weeks in healthy female participants with sensitive, oily, blemish-prone skin.

Condition or Disease Intervention/Treatment Phase
  • Other: Washout / Standard Cleanser
  • Other: Test product
  • Other: Positive control cleanser
  • Other: Positive control moisturiser
N/A

Detailed Description

This study broadly consists of two phases: screening / washout phase (5-7 day) followed by treatment phase (approximately of 8 weeks). Participants will be asked to return to the study site 1 week, 4 weeks and 8 weeks after their randomisation visit for instrumental measurements and clinical assessments.

Study Design

Study Type:
Interventional
Actual Enrollment :
157 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized, Parallel-group, Evaluator-blind, No-treatment and Positive Controlled, Single-site, Proof of Concept Clinical Study to Evaluate the Cosmetic Benefit Provided by 8 Weeks of Twice-daily Topical Application of a Developmental Moisturizing Cream With Niacinamide in Healthy Subjects With Sensitive, Oily, Blemish-prone Skin
Actual Study Start Date :
Apr 4, 2017
Actual Primary Completion Date :
Aug 28, 2017
Actual Study Completion Date :
Aug 28, 2017

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: No treatment and Standard cleanser

Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.

Other: Washout / Standard Cleanser
Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study

Experimental: Test product and Standard cleanser

Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.

Other: Washout / Standard Cleanser
Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study

Other: Test product
Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.

Active Comparator: Positive control and positive cleanser

Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.

Other: Positive control cleanser
Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.

Other: Positive control moisturiser
Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Corneometer Values at 8 Hours on Day 1 [At Baseline and Day 1]

    A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturization.Measurement of skin moisturization was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content.The range of hydration level was 0 (as dry as possible)~120 AU (Arbitrary Unit)(most moist possible).Higher Corneometer values are indicative of improved skin moisturization.

Secondary Outcome Measures

  1. Change From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8 [At Baseline, Day 1, Week 1, 4 and 8]

    A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturisation. Measurement of skin moisturisation was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. Higher Corneometer values are indicative of improved skin moisturisation.

  2. Odds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline [At Baseline and Week 8]

    The baseline and week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting and all practical efforts were made to minimize glare. The relative positioning (left and right) of baseline and week 8 photographs were blinded to evaluator and randomized. A technician used randomization schedule to display pair of images to lay evaluator. Lay evaluators judged magnitude of improvement in overall appearance of blemishes using the below criteria: Left=blemishes on left are more obvious than those on the right and Right=blemishes on right are more obvious than those on the left. Layperson ranked both left and right image as follows:1=Better;2=Worse. Odds was calculated from logistic regression including treatment and age stratum effects and exchangeable correlation. Odds=p/(1-p) where p was the probability of event that Week 8 was better than baseline.

  3. ANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline [At Baseline and Week 8]

    Baseline and Week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting with minimized glare. Relative positioning (left and right) of baseline and Week 8 photographs were blinded to evaluator and randomized. Lay evaluators ranked magnitude of improvement in overall appearance of blemishes using below criteria: Left=blemishes on left are more obvious than those on right; Right=blemishes on right are more obvious than those on left. Lay evaluator ranking for each image pair was converted into a numerical score based on whether Baseline or Week 8 image was ranked better:0=Baseline image was better than Week 8 image,1=Week 8 image was better than Baseline image. Minimum score 0 corresponded to all baseline images being better than Week 8 images. Maximum score 1 corresponded to all Week 8 images being better than baseline images. Higher scores indicated better results.

  4. Change From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8 [At Baseline, Week 1, 4 and 8]

    A treatment blind, trained and qualified evaluator counted the total number of facial blemishes on the forehead, cheeks and chin of the participants.

  5. Change From Baseline in Sebumeter Values at Week 1, 4 and 8 [At Baseline, Week 1, 4 and 8]

    A treatment blinded, trained and qualified evaluator conducted instrumental measurements of skin sebum levels. Measurement of skin sebum levels was performed by with a Sebumeter SM 815. The measurement principle of the SM 815 is based on grease spot photometry. The translucent tape of the device is brought into contact with skin and becomes increasingly transparent in response to surface oil. The tape is inserted into the aperture of the device and its transparency measured by light transmission, with increased transmission signifying increased oiliness. The software outputs mass sebum levels as a function of area. Sebumeter measurements were taken in triplicate at the central forehead (above the eyebrows) with the participant lying horizontally, on their back.

  6. Change From Baseline in Sebum Excretion Rate at Week 1, 4 and 8 [At Baseline, Week 1, 4 and 8]

    The forehead of each participant was thoroughly cleansed by the investigator or designee using cotton pads saturated with 70% Isopropyl Alcohol and, after 5 minutes, the central area of the forehead above the eyebrows was measured in triplicate with a Sebumeter. The same area was measured in triplicate 90 minutes after cleansing. The sebum excretion rate was calculated by the difference in 90th minutes and 5th minute Sebumeter values.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form

  • Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination

  • Willingness to actively participate in the study and to attend all scheduled visits

  • Minimum of 10 and maximum of 25 blemishes (papules and pustules) at Visit 1 and a minimum of 8 blemishes (papules and pustules) at Visit 2

  • Fitzpatrick photo-type I-V

  • Sebumeter score of >66 µg / cm2 at the forehead

  • Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone OR injectable progestogen OR implants of levonorgestrel OR estrogenic vaginal ring OR percutaneous contraceptive patches OR intrauterine device or intrauterine system OR double barrier method (condom or occlusive cap [diaphragm or cervical vault caps] plus spermicidal agent [foam, gel, film, cream, suppository]) OR male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant

  • Cleanses their face at least once a day

Exclusion Criteria:
  • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study

  • Women who are breast-feeding

  • Medical history of using a medicated acne treatment (e.g. Benzoyl Peroxide, Clindamycin, isotretinoin) within the last 12 months

  • Change in contraception within the last 3 months

  • Active skin disease in the test area

  • Medical history of dysplastic nevi or melanoma on the face

  • Moles, cysts, tattoos, scars, irritated skin, hairs, etc. at the test area that could influence the investigation

  • Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines within 7 days prior to the start of the study and/or throughout the entire course of the study

  • Systemic use of anti-microbials within the last month

  • Systemic use of over-the-counter (OTC) analgesics or anti-inflammatory drugs 24 hours prior to dosing at the first assessment visit

  • One of the following illnesses that might require regular systemic medication: Insulin-dependent diabetes, cancer

  • One of the following illnesses if not medicated: Asthma, hypertension

  • Medical history of abnormal response to sunlight

  • History of mental illness

  • Medically diagnosed acne vulgaris, acne conglobate, fulminans, secondary acne (drug induced acne) or any acne requiring systemic or topical treatment

  • No aesthetic, cosmetic or dermatological treatment in the treatment area (face) within the last month

  • No intense sun exposure, Ultraviolet-treatments or tanning salon visit within the last 2 weeks

  • Known or suspected intolerance, allergy or hypersensitivity to study materials (or closely related compounds) or any of their stated ingredients

  • History of allergies to cosmetic products or medicated acne treatments

  • Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit

  • Previous participation in this study

  • Recent history (within the last 5 years) of alcohol or other substance abuse

  • An employee of the sponsor or the study site or members of their immediate family

Contacts and Locations

Locations

Site City State Country Postal Code
1 GSK Investigational Site Valinhos Brazil 13271-130

Sponsors and Collaborators

  • GlaxoSmithKline

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study Documents (Full-Text)

More Information

Additional Information:

Publications

None provided.
Responsible Party:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT03093181
Other Study ID Numbers:
  • 207196
First Posted:
Mar 28, 2017
Last Update Posted:
Feb 24, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

Participant Flow

Recruitment Details All the participants were recruited from one center in Brazil.
Pre-assignment Detail Out of 205 screened participants,157 participants were enrolled, and 132 participants were randomized. 25 enrolled subjects were not subsequently randomized. Out of 132 randomized participants,1 participant was misallocated to treatment (received "no treatment" instead of "positive control").
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Period Title: Overall Study
STARTED 44 44 44
COMPLETED 41 42 41
NOT COMPLETED 3 2 3

Baseline Characteristics

Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen Total
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing. Total of all reporting groups
Overall Participants 44 45 43 132
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]
25.4
(5.82)
25.8
(6.05)
24.8
(5.72)
25.3
(5.84)
Sex: Female, Male (Count of Participants)
Female
44
100%
45
100%
43
100%
132
100%
Male
0
0%
0
0%
0
0%
0
0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
3
6.8%
5
11.1%
0
0%
8
6.1%
Asian
0
0%
0
0%
1
2.3%
1
0.8%
Native Hawaiian or Other Pacific Islander
0
0%
0
0%
0
0%
0
0%
Black or African American
14
31.8%
10
22.2%
18
41.9%
42
31.8%
White
27
61.4%
30
66.7%
24
55.8%
81
61.4%
More than one race
0
0%
0
0%
0
0%
0
0%
Unknown or Not Reported
0
0%
0
0%
0
0%
0
0%

Outcome Measures

1. Primary Outcome
Title Change From Baseline in Corneometer Values at 8 Hours on Day 1
Description A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturization.Measurement of skin moisturization was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content.The range of hydration level was 0 (as dry as possible)~120 AU (Arbitrary Unit)(most moist possible).Higher Corneometer values are indicative of improved skin moisturization.
Time Frame At Baseline and Day 1

Outcome Measure Data

Analysis Population Description
Intent to treat (ITT, N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 43
Mean (Standard Deviation) [Arbitrary Corneometer unit]
6.14
(6.442)
2.63
(5.602)
3.60
(7.860)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Test Product Regimen, No Treatment Regimen
Comments
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.0128
Comments From Analysis of covariance (ANCOVA) with treatment main effect, age stratum and baseline as covariates
Method ANCOVA
Comments
Method of Estimation Estimation Parameter Least square (LS) mean difference
Estimated Value 3.12
Confidence Interval (2-Sided) 95%
0.68 to 5.56
Parameter Dispersion Type:
Value:
Estimation Comments Difference is first named treatment (test product) minus second named treatment (negative control) such that a positive value favors the first named treatment (test product).
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection No Treatment Regimen, Positive Control Regimen
Comments
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.2262
Comments From ANCOVA with treatment main effect, age stratum and baseline as covariates.
Method ANCOVA
Comments
Method of Estimation Estimation Parameter LS mean difference
Estimated Value 1.51
Confidence Interval (2-Sided) 95%
-0.95 to 3.96
Parameter Dispersion Type:
Value:
Estimation Comments Difference is first named treatment (test product) minus second named treatment (negative control) such that a positive value favors the first named treatment (test product).
2. Secondary Outcome
Title Change From Baseline in Corneometer Values at 1 and 3 Hours on Day 1 and at Week 1, 4 and 8
Description A blinded, trained and qualified evaluator conducted instrumental measurements of skin moisturisation. Measurement of skin moisturisation was performed by the electrical capacitance method with a Corneometer CM 865. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field was built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. Higher Corneometer values are indicative of improved skin moisturisation.
Time Frame At Baseline, Day 1, Week 1, 4 and 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
At 1 hour, Day 1
11.52
(8.264)
-3.69
(6.150)
4.55
(8.055)
At 3 hour, Day 1
9.64
(5.986)
0.68
(5.029)
4.33
(7.913)
At Week 1
4.39
(10.549)
0.06
(9.024)
3.31
(11.027)
At Week 4
4.33
(8.935)
3.16
(7.028)
1.04
(8.124)
At Week 8
7.54
(11.994)
3.32
(10.059)
2.51
(12.969)
3. Secondary Outcome
Title Odds for Logistic Regression Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline
Description The baseline and week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting and all practical efforts were made to minimize glare. The relative positioning (left and right) of baseline and week 8 photographs were blinded to evaluator and randomized. A technician used randomization schedule to display pair of images to lay evaluator. Lay evaluators judged magnitude of improvement in overall appearance of blemishes using the below criteria: Left=blemishes on left are more obvious than those on the right and Right=blemishes on right are more obvious than those on the left. Layperson ranked both left and right image as follows:1=Better;2=Worse. Odds was calculated from logistic regression including treatment and age stratum effects and exchangeable correlation. Odds=p/(1-p) where p was the probability of event that Week 8 was better than baseline.
Time Frame At Baseline and Week 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
For Polarised Image
1.84
1.00
1.04
For Non-polarised Image
2.06
1.08
1.02
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Test Product Regimen, No Treatment Regimen
Comments Analysis of Lay Person Assessment Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.0243
Comments
Method Odds Ratio
Comments
Method of Estimation Estimation Parameter Odds Ratio (OR)
Estimated Value 1.85
Confidence Interval (2-Sided) 95%
1.08 to 3.15
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection No Treatment Regimen, Positive Control Regimen
Comments Analysis of Lay Person Assessment Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.8931
Comments
Method Odds Ratio
Comments
Method of Estimation Estimation Parameter Odds Ratio (OR)
Estimated Value 1.04
Confidence Interval (2-Sided) 95%
0.61 to 1.78
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 3
Statistical Analysis Overview Comparison Group Selection Test Product Regimen, No Treatment Regimen
Comments Analysis of Lay Person Assessment Non-Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.0181
Comments
Method Odds Ratio
Comments
Method of Estimation Estimation Parameter Odds Ratio (OR)
Estimated Value 1.90
Confidence Interval (2-Sided) 95%
1.12 to 3.25
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 4
Statistical Analysis Overview Comparison Group Selection No Treatment Regimen, Positive Control Regimen
Comments Analysis of Lay Person Assessment Non-Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.8319
Comments
Method Odds Ratio
Comments
Method of Estimation Estimation Parameter Odds Ratio (OR)
Estimated Value 0.94
Confidence Interval (2-Sided) 95%
0.55 to 1.63
Parameter Dispersion Type:
Value:
Estimation Comments
4. Secondary Outcome
Title ANOVA Analysis on Improvement Rating of Lay Person Assessment of Polarized and Non-polarized Images Week 8 Compared to Baseline
Description Baseline and Week 8 photographs of all participants were displayed side by side on high resolution, color-calibrated display screen in room with neutral wall colors and standardized lighting with minimized glare. Relative positioning (left and right) of baseline and Week 8 photographs were blinded to evaluator and randomized. Lay evaluators ranked magnitude of improvement in overall appearance of blemishes using below criteria: Left=blemishes on left are more obvious than those on right; Right=blemishes on right are more obvious than those on left. Lay evaluator ranking for each image pair was converted into a numerical score based on whether Baseline or Week 8 image was ranked better:0=Baseline image was better than Week 8 image,1=Week 8 image was better than Baseline image. Minimum score 0 corresponded to all baseline images being better than Week 8 images. Maximum score 1 corresponded to all Week 8 images being better than baseline images. Higher scores indicated better results.
Time Frame At Baseline and Week 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
For Polarised Image
0.65
(0.048)
0.50
(0.047)
0.51
(0.047)
For Non-polarised Image
0.67
(0.047)
0.52
(0.046)
0.51
(0.047)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Test Product Regimen, No Treatment Regimen
Comments Analysis of Lay Person Assessment Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.0279
Comments
Method ANOVA
Comments ANOVA= average rate over all raters including effects of treatment and age stratum.
Method of Estimation Estimation Parameter Mean Difference (Final Values)
Estimated Value 0.15
Confidence Interval (2-Sided) 95%
0.02 to 0.28
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection No Treatment Regimen, Positive Control Regimen
Comments Analysis of Lay Person Assessment Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.8887
Comments
Method ANOVA
Comments ANOVA= average rate over all raters including effects of treatment and age stratum.
Method of Estimation Estimation Parameter Mean Difference (Final Values)
Estimated Value 0.01
Confidence Interval (2-Sided) 95%
-0.12 to 0.14
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 3
Statistical Analysis Overview Comparison Group Selection Test Product Regimen, No Treatment Regimen
Comments Analysis of Lay Person Assessment Non-Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.0224
Comments
Method ANOVA
Comments ANOVA= average rate over all raters including effects of treatment and age stratum.
Method of Estimation Estimation Parameter Mean Difference (Final Values)
Estimated Value 0.15
Confidence Interval (2-Sided) 95%
0.02 to 0.28
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 4
Statistical Analysis Overview Comparison Group Selection No Treatment Regimen, Positive Control Regimen
Comments Analysis of Lay Person Assessment Non-Polarised Image.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.8253
Comments
Method ANOVA
Comments ANOVA= average rate over all raters including effects of treatment and age stratum.
Method of Estimation Estimation Parameter Mean Difference (Final Values)
Estimated Value -0.01
Confidence Interval (2-Sided) 95%
-0.15 to 0.12
Parameter Dispersion Type:
Value:
Estimation Comments
5. Secondary Outcome
Title Change From Baseline in Evaluator's Assessment of Total Blemish Count at Week 1, 4, and 8
Description A treatment blind, trained and qualified evaluator counted the total number of facial blemishes on the forehead, cheeks and chin of the participants.
Time Frame At Baseline, Week 1, 4 and 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
At Week 1
-0.70
(4.338)
-1.05
(3.331)
-0.93
(3.460)
At Week 4
-3.86
(3.143)
-2.76
(4.154)
-4.00
(4.461)
At Week 8
-5.68
(3.889)
-3.79
(3.626)
-5.12
(4.507)
6. Secondary Outcome
Title Change From Baseline in Sebumeter Values at Week 1, 4 and 8
Description A treatment blinded, trained and qualified evaluator conducted instrumental measurements of skin sebum levels. Measurement of skin sebum levels was performed by with a Sebumeter SM 815. The measurement principle of the SM 815 is based on grease spot photometry. The translucent tape of the device is brought into contact with skin and becomes increasingly transparent in response to surface oil. The tape is inserted into the aperture of the device and its transparency measured by light transmission, with increased transmission signifying increased oiliness. The software outputs mass sebum levels as a function of area. Sebumeter measurements were taken in triplicate at the central forehead (above the eyebrows) with the participant lying horizontally, on their back.
Time Frame At Baseline, Week 1, 4 and 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
At Week 1
-54.98
(133.157)
-70.50
(131.654)
-52.19
(116.797)
At Week 4
-49.57
(128.821)
-67.52
(139.278)
-21.67
(114.170)
At Week 8
-86.49
(118.708)
-87.04
(114.207)
-65.85
(111.936)
7. Secondary Outcome
Title Change From Baseline in Sebum Excretion Rate at Week 1, 4 and 8
Description The forehead of each participant was thoroughly cleansed by the investigator or designee using cotton pads saturated with 70% Isopropyl Alcohol and, after 5 minutes, the central area of the forehead above the eyebrows was measured in triplicate with a Sebumeter. The same area was measured in triplicate 90 minutes after cleansing. The sebum excretion rate was calculated by the difference in 90th minutes and 5th minute Sebumeter values.
Time Frame At Baseline, Week 1, 4 and 8

Outcome Measure Data

Analysis Population Description
ITT (N= 132) population included all participants who were randomized into the study and have at least one post-baseline measurement available.
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
Measure Participants 44 44 44
At Week 1
20.36
(135.959)
38.72
(149.325)
66.73
(161.570)
At Week 4
30.49
(153.074)
44.97
(125.342)
53.17
(137.181)
At Week 8
38.04
(162.934)
32.91
(148.784)
67.10
(112.039)

Adverse Events

Time Frame Approximately 57 days
Adverse Event Reporting Description 1 participant was misallocated to treatment (received "no treatment" instead of "positive control"). This means 45 participants were in safety population for "no treatment".However, per convention, ITT population is defined based on intended treatment allocation.While 1 subject incorrectly received "no treatment",they were initially allocated to "positive control". Therefore, this participant was included in ITT population for "positive control" but safety population for "no treatment".
Arm/Group Title Test Product Regimen No Treatment Regimen Positive Control Regimen
Arm/Group Description Participants randomized to test product regimen used the standard cleanser and test product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the test product cream immediately after cleansing. Participants randomized to the no treatment regimen used the standard cleanser (only) twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants randomized to positive control regimen used the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications were separated by at least 8 hours. Participants applied the positive control cream immediately after cleansing.
All Cause Mortality
Test Product Regimen No Treatment Regimen Positive Control Regimen
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/44 (0%) 0/45 (0%) 0/43 (0%)
Serious Adverse Events
Test Product Regimen No Treatment Regimen Positive Control Regimen
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/44 (0%) 0/45 (0%) 0/43 (0%)
Other (Not Including Serious) Adverse Events
Test Product Regimen No Treatment Regimen Positive Control Regimen
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 1/44 (2.3%) 2/45 (4.4%) 5/43 (11.6%)
Gastrointestinal disorders
ABDOMINAL PAIN UPPER 0/44 (0%) 0/45 (0%) 1/43 (2.3%)
NAUSEA 0/44 (0%) 0/45 (0%) 1/43 (2.3%)
Nervous system disorders
HEADACHE 1/44 (2.3%) 1/45 (2.2%) 3/43 (7%)
HYPERAESTHESIA 0/44 (0%) 0/45 (0%) 1/43 (2.3%)
Respiratory, thoracic and mediastinal disorders
NASAL DISCOMFORT 0/44 (0%) 0/45 (0%) 1/43 (2.3%)
Skin and subcutaneous tissue disorders
DERMATITIS CONTACT 0/44 (0%) 1/45 (2.2%) 0/43 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Results Point of Contact

Name/Title GSK Response Center
Organization GlaxoSmithKline
Phone 866-435-7343
Email GSKClinicalSupportHD@gsk.com
Responsible Party:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT03093181
Other Study ID Numbers:
  • 207196
First Posted:
Mar 28, 2017
Last Update Posted:
Feb 24, 2020
Last Verified:
Feb 1, 2020